Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 70, Issue 12, 2015, Pages 1559-1568

  Siebeneicher, S ^a   Reuter, S ^b,c   Wangorsch, A ^a   Krause, M ^a   Foetisch, K ^a   Heinz, A ^b   Naito, S ^d   Reuter, A ^a   Taube, C ^e   Vieths, S ^a   Scheurer, S ^a   Toda, M ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c RESEARCH CENTER BORSTEL   (Germany)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

birch pollen allergy; epicutaneous immunization; hypoallergen

Indexed keywords

CD11B ANTIGEN; CYTOKINE; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; POLLEN EXTRACT; RECOMBINANT BET V 1; RECOMBINANT BET V 1B2; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; ALLERGEN; BET V 1 ALLERGEN, BETULA; ISOPROTEIN; PLANT ANTIGEN;

ALLERGIC ASTHMA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; EOSINOPHIL; FEMALE; HISTOPATHOLOGY; IMMUNOBLOTTING; IMMUNOGENICITY; IMMUNOTHERAPY; LUNG FUNCTION; LUNG LAVAGE; MOUSE; NONHUMAN; POLLEN ALLERGY; PRIORITY JOURNAL; TH2 CELL; ANIMAL; ASTHMA; BAGG ALBINO MOUSE; CHEMISTRY; DESENSITIZATION; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGY; PROCEDURES; RESPIRATORY HYPERSENSITIVITY; RHINITIS, ALLERGIC, SEASONAL;

ALLERGENS; ANIMALS; ANTIGENS, PLANT; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOBLOTTING; MICE; MICE, INBRED BALB C; PROTEIN ISOFORMS; RECOMBINANT PROTEINS; RESPIRATORY HYPERSENSITIVITY; RHINITIS, ALLERGIC, SEASONAL;

EID: 84983103047     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12732     Document Type: Article

References (40)

1. Werfel T,. Epicutaneous allergen administration: a novel approach for allergen-specific immunotherapy? J Allergy Clin Immunol 2009; 124: 1003-1004.
2. Senti G, von Moos S, Tay F, Graf N, Sonderegger T, Johansen P, et al., Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012; 129: 128-135.
3. Dupont C, Kalach N, Soulaines P, Legoué-Morillon S, Piloquet H, Benhamou PH,. Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 2010; 125: 1165-1167.
4. Senti G, von Moos S, Kündig TM,. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy 2011; 66: 798-809.
5. von Moos S, Johansen P, Tay F, Graf N, Kündig TM, Senti G,. Comparing safety of abrasion and tape-stripping as skin preparation in allergen-specific epicutaneous immunotherapy. J Allergy Clin Immunol 2014; 134: 965-967.
6. Ferreira F, Briza P, Inführ D, Schmidt G, Wallner M, Wopfner N, et al., Modified recombinant allergens for safer immunotherapy. Inflamm Allergy Drug Targets 2006; 5: 5-14.
7. Grönlund H, Gafvelin G,. Recombinant Bet v 1 vaccine for treatment of allergy to birch pollen. Hum Vaccin 2010; 12: 970-977.
8. Linhart B, Valenta R,. Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives. Vaccine 2012; 30: 4328-4335.
9. Cromwell O, Häfner D, Nandy A,. Recombinant allergens for specific immunotherapy. J Allergy Clin Immunol 2011; 127: 865-872.
10. Moverare R, Elfman L, Vesterinen E, Metso T, Haahtela T,. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 2002; 57: 423-430.
11. D'Amato G, Cecchi L, Bonini S, Nunes C, Annesi-Maesano I, Behrendt H, et al., Allergenic pollen and pollen allergy in Europe. Allergy 2007; 62: 976-990.
12. Villalba M, Rodríguez R, Batanero E,. The spectrum of olive pollen allergens. From structures to diagnosis and treatment. Methods 2014; 66: 44-54.
13. Bublin M, Breiteneder H,. Developing therapies for peanut allergy. Int Arch Allergy Immunol 2014; 165: 179-194.
14. Gajhede M, Osmark P, Poulsen FM, Ipsen H, Larsen JN, Joost van Neerven RJ, et al., X-ray and NMR structure of Bet v 1, the origin of birch pollen allergy. Nat Struct Biol 1996; 3: 1040-1045.
15. Kahlert H, Suck R, Weber B, Nandy A, Wald M, Keller W, et al., Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Int Arch Allergy Immunol 2008; 145: 193-206.
16. Ferreira F, Ebner C, Kramer B, Casari G, Briza P, Kungl AJ, et al., Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J 1998; 12: 231-242.
17. Son DY, Scheurer S, Hofmann A, Haustein D, Vieths S,. Pollen-related food allergy: cloning and immunological analysis of isoforms and mutants of Mal d 1, the major apple allergen, and Bet v 1, the major birch pollen allergen. Eur J Nutr 1999; 38: 201-215.
18. Scheurer S, Son DY, Boehm M, Karamloo F, Franke S, Hoffmann A, et al., Cross-reactivity and epitope analysis of Pru a 1, the major cherry allergen. Mol Immunol 1999; 36: 155-167.
19. Holm J, Gajhede M, Ferreras M, Henriksen A, Ipsen H, Larsen JN, et al., Allergy vaccine engineering: epitope modulation of recombinant Bet v 1 reduces IgE binding but retains protein folding pattern for induction of protective blocking-antibody responses. J Immunol 2004; 173: 5258-5267.
20. Campana R, Vrtala S, Maderegger B, Jertschin P, Stegfellner G, Swoboda I, et al., Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly. J Allergy Clin Immunol 2010; 126: 1024-1031.
21. Vrtala S, Hirtenlehner K, Vangelista L, Pastore A, Eichler HG, Sperr WR, et al., Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 1997; 99: 1673-1681.
22. Purohit A, Niederberger V, Kronqvist M, Horak F, Grönneberg R, Suck R, et al., Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 2008; 38: 1514-1525.
23. Vrtala S, Fohr M, Campana R, Baumgartner C, Valent P, Valenta R,. Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. Vaccine 2011; 29: 2140-2148.
24. Schoell I, Kalkura N, Shedziankova Y, Bergmann A, Verdino P, Knittelfelder R, et al., Dimerization of the major birch pollen allergen Bet v 1 is important for its in vivo IgE-cross-linking potential in mice. J Immunol 2005; 175: 6645-6650.
25. Zaborsky N, Brunner M, Wallner M, Himly M, Karl T, Schwarzenbacher R, et al., Antigen aggregation decides the fate of the allergic immune response. J Immunol 2010; 184: 725-735.
26. Larché M,. Peptide immunotherapy for allergic diseases. Allergy 2007; 62: 325-331.
27. Akdis CA, Akdis M,. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011; 127: 18-27.
28. Siebeneicher S, Reuter S, Krause M, Wangorsch A, Maxeiner J, Wolfheimer S, et al., Epicutaneous immune modulation with Bet v 1 plus R848 suppresses allergic asthma in a murine model. Allergy 2014; 69: 328-337.
29. Reuter S, Dehzad N, Martin H, Böhm L, Becker M, Buhl R, et al., TLR3 but not TLR7/8 ligand induces allergic sensitization to inhaled allergen. J Immunol 2012; 188: 5123-5131.
30. Kitzmueller C, Wallner M, Deifl S, Mutschlechner S, Walterskirchen C, Zlabinger GJ, et al., A hypoallergenic variant of the major birch pollen allergen shows distinct characteristics in antigen processing and T-cell activation. Allergy 2012; 67: 1375-1382.
31. Palmqvist C, Wardlaw AJ, Bradding P,. Chemokines and their receptors as potential targets for the treatment of asthma. Br J Pharmacol 2007; 151: 725-736.
32. + T cell migration. J Immunol 2013; 190: 4500-4507.
33. Eisenbarth SC, Piggott DA, Bottomly K,. The master regulators of allergic inflammation: dendritic cells in Th2 sensitization. Curr Opin Immunol 2003; 15: 620-626.
34. Fonseca DM, Wowk PF, Paula MO, Gembre AF, Baruffi MD, Fermino ML, et al., Requirement of MyD88 and Fas pathways for the efficacy of allergen-free immunotherapy. Allergy 2015; 70: 275-284.
35. Swamy M, Jamor C, Havran W, Hayday A,. Epithelial decision makers: in search of the 'epimmunome'. Nat Immunol 2010; 11: 656-665.
36. Pellerin L, Jenks JA, Bégin P, Bacchetta R, Nadeau KC,. Regulatory T cells and their roles in immune dysregulation and allergy. Immunol Res 2014; 58: 358-368.
37. Beck LA, Leung DY,. Allergen sensitization through the skin induces systemic allergic responses. J Allergy Clin Immunol 2000; 106 (5 Suppl): S258-S263.
38. Stremnitzer C, Manzano-Szalai K, Starkl P, Willensdorfer A, Schrom S, Singer J, et al., Epicutaneously applied Der p 2 induces a strong TH2-biased antibody response in C57BL/6 mice, independent of functional TLR4. Allergy 2014; 69: 741-751.
39. Scheurer S, Toda M, Vieths S,. What makes an allergen? Clin Exp Allergy 2015; 45: 1150-1161.
40. Husslik F, Hanschmann KM, Krämer A, Seutter von Loetzen C, Schweimer K, Bellinghausen I, et al., Folded or Not? Tracking Bet v 1 Conformation in Recombinant Allergen Preparations. PLoS ONE 2015; 10: e0132956.